Following on from information provided to NICE by the company in May 2023 the appraisal of Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| ID number | 4050 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 May 2023 | Discontinued. Following on from information provided to NICE by the company in May 2023 the appraisal of Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 May 2022 | For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes |
For further information on our processes and methods, please see our CHTE processes and methods manual